Predictors of a sustained beneficial response to interferon alfa therapy in chronic hepatitis C

Hepatology

Volumn 22, Issue 4 PART 1, 1995, Pages 1326-1329

  Conjeevaram, Hari S ^a   Everhart, James E ^a   Hoofnagle, Jay H ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ALPHA INTERFERON; VIRUS RNA;

DRUG EFFICACY; EDITORIAL; HEPATITIS C; HISTOPATHOLOGY; HUMAN; IMMUNOTHERAPY; LONG TERM CARE; PREDICTION; PRIORITY JOURNAL; VIRUS INHIBITION;

CHRONIC DISEASE; GAMMA-GLUTAMYLTRANSFERASE; HEPATITIS C; HUMAN; INTERFERON TYPE I, RECOMBINANT; LIVER CIRRHOSIS;

EID: 0029125815     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1016/0270-9139(95)90646-0     Document Type: Editorial

References (30)

1. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon
2. Treatment of chronic hepatitis C with recombinant interferon alpha: a multicenter randomized, controlled trial
3. Recombinant interferon alpha therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial
4. Therapy of chronic post-transfusion non-A non-B hepatitis with interferon alfa-2b Swedish experience
5. Recombinant human-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France
6. Long-term follow-up of patients with chronic hepatitis C treated with alpha-interferon
7. Treatment of chronic hepatitis C efficacy of interferon dose and analysis of factors predictive of response interim report of 350 patients treated in a Benelux multicenter study
8. Comparative efficacy of interferon alpha in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis
9. Predictors of response to alpha-interferon (IFN) in chronic hepatitis C: a multivariate analysis on 361 treated patients
10. Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon-2b
11. Prediction of the response of chronic hepatitis C to interferon alfa: a statistical analysis of pretreatment variables
12. Factors predictive of response to interferon-a therapy in hepatitis C virus infection
13. A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C
14. Prediction of interferon effect in chronic hepatitis C by both quantification and genotyping of HCV-RNA
15. Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer
16. 2a therapy in patients with chronic hepatitis C
17. Relationship between serum HCV markers and response to interferon therapy in chronic hepatitis C
18. Genotypic analysis of hepatitis C virus in American patients
19. Genotypes and titres of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C
20. Hepatitis C virus type lb infection in France and Italy
21. Analysis of clinical and virological factors associated with response to alpha interferon therapy in chronic hepatitis C
22. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial
23. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-a therapy: relationship to genotypes of hepatitis C virus
24. Quantitation and typing of serum hepatitis C virus RNA in patients with chronic hepatitis C treated with inteferon-B
25. Clinical and histologic predictors of response to interferon-alpha in patients with chronic hepatitis C viral infection
26. Clinical predictors of response to recombinant interferon-alpha treatment in patients with chronic hepatitis non-A, non-B hepatitis (hepatitis C)
27. Response to interferon a therapy is influenced by the iron content of the liver
28. Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C
29. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C
30. Pretreatment serum HCV RNA levels and HCV genotype are the main and independent prognostic factors of sustained response to alpha interferon therapy in chronic hepatitis C